⟵ Back to Search Results

BGB-A317-214

Not yet recruiting

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Beigene Study ID info

BGB-A317-214

ClinicalTrials.gov ID info

NCT05116085

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

You will be redirected to

Click the link above to continue or CANCEL